Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q2 2022 Earnings Presentation
26 slides from Observe Medical ASA's earnings presentation, Aug 25, 2022
Slide 1: Q2 and Half Year 2022 Results
Q2 and Half Year 2022 Results 25 August 2022 1
Slide 2: Copyright and disclaimer
OBSERVE MEDICAL Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be repr
Slide 3: Presenting team
INTRODUCTION Presenting team Rune Nystad Per Arne Nygård Chief Executive Officer Chief Financial Officer Observe Medical Observe Medical 20+ years of experience from global 20+ years of experience from finance medtech and industrial technology from and accounting in various sectors the Nordics, US,
Slide 4: Nordic medtech company with global reach
WHO WE ARE | WHAT WE DO Nordic medtech company with global reach Commercializing proprietary innovative medtech products on a global market International distributor and partner network and Nordic direct sales operations Solid platform for further organic growth and through targeted M&A Fundamendal
Slide 5: What will take us there?
What will take us there? THE FUNDAMENT OF OUR BUSINESS AND VALUE CREATION Significant growth targets supported by a powerful and scalable medtech platform 1 With two proprietary products on the market – Biim and Sippi® Portfolio with synergy opportunities, which allows for accelerated commercial rol
Slide 6: Financial Highlights first half year of 2022
FINANCIALS FIRST HALF YEAR 2022 Financial Highlights first half year of 2022 Revenue and gross results* Revenues Revenues • Gross margin improved to 39.7% (up 12,009 12,846 2.5pp) driven by increased sale of proprietary products • Total revenues at NOK 12 million, of which revenues from sales of Bii
Slide 7: Biim: Fresenius partnership on track
Biim: Fresenius partnership on track • A total of 260 Biim probes have been delivered to Fresenius educational centres • Biim roll-out with Fresenius continues as planned across educational centres throughout the USA – Strong engagement with Fresenius c-level team to ensure implementation and succes
Slide 8: Biim: Strong engagement with Fresenius in roll-out
Biim: Strong engagement with Fresenius in roll-out Example educational video to further drive adoption 8
Slide 9: Sippi®: Preparation for scale-up underway
Sippi®: Preparation for scale-up underway • New production and manufacturing partner confirmed in Italy – Previous supplier closed down production in Belarus • Increased interest in Sippi® internationally – Supporting efficiency in the ICU and the growing nursing gap • Sippi® Disposable Unit achieve
Slide 10: Nordic sales and distribution platform: additional contracts signed
Nordic sales and distribution platform: additional contracts signed Medtech portfolio • Four contracts signed this year with an estimated of devices and disposables potential total annual volume of NOK 5.5 million, including: – Anaesthesia tubes in Stockholm, Uppsala, Mora, 35 active contracts with
Slide 11: Q2 2022 financials
Q2 2022 financials 11
Slide 12: Financial Highlights first half year 2022
FINANCIALS FIRST HALF YEAR 2022 Financial Highlights first half year 2022 Revenue split H1 2021 vs H1 2022* (Amounts in NOK thousand) Sippi Sales performance Sippi 125 Other 146 44 • Total revenues of NOK 12 million first half year 2022 Biim Safety probe Nordic • Revenues from sales of Biim ultrasou
Slide 13: Key figures Profit and loss statement
FINANCIAL REVIEW Key figures Profit and loss statement Amounts in NOK thousand • Revenues first half year positive (excl. earnings per share) Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 impacted by revenues from Biim mainly in Q1, second quarter 2021 Operating revenues 4 296 9 737 12 009 12 846 24 042 d
Slide 14: Key figures Financial position
FINANCIAL REVIEW Key figures Financial position Amounts in NOK million • Cash of NOK 40.5 million, impacted by – Net proceeds from Rights Issue – Cash settlement Biim NOK 40.5 million NOK 7.5 million Ultrasound acquisition – Repayment interest-bearing debt – Cash used in operating activities Cash NI
Slide 15: Key figures Cash flow statement for the first half year 2022
FINANCIAL REVIEW Key figures Cash flow statement for the first half year 2022 Amounts in NOK thousand • Cash flow used in operating activities mainly related to the EBIT result H1 2022 impacted by 315 the Biim acquisition and 45 000 121,301 40,478 decreased result from the Nordic 35 000 portfolio 25
Slide 16: Concluding remarks and outlook
Concluding remarks and outlook • Status – Biim probes now available across all Fresenius educational clinics – the leading provider of kidney care services in the US – New manufacturing partner secured for Sippi – Blueprint for combined organisation in place • Current, immediate priorities – Move to
Slide 17: Q&A
O&A oReonserve medical
Slide 18: Q2 and First Half Year 2022 financials Appendix
Q2 and First Half Year 2022 financials Appendix 18
Slide 19: Consolidated Statement of Comprehensive Income
UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2022 Consolidated Statement of Comprehensive Income (Amounts in NOK thousand) Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 Operating revenues 4 296 9 737 12 009 12 846 24 042 Cost of materials 2 891 5 799 7 237 8 064 14 524 Gross result 1 405 3 938 4 772 4 782 9 519
Slide 20: Statement of financial position
UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2022 Statement of financial position (Amounts in NOK thousand) At 30 June 2022 At 30 June 2021 At 31 December 2021 ASSETS Non-current assets Goodwill 86 697 34 965 33 870 Intangible assets 99 753 20 265 21 328 Tangible assets 3 656 1 849 1 381 Total non-current
Slide 21: Statement of financial position
UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2022 Statement of financial position (Amounts in NOK thousand) At 30 June 2022 At 30 June 2021 At 31 December 2021 EQUITY AND LIABILITIES Total equity 174 064 11 800 -14 122 Non-current liabilities Non-current lease liabilities 1 307 1 033 550 Contingent consid
Slide 22: Statement of changes in equity
UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2022 Consolidated Statement of Comprehensive Income Other paid-in Total paid-in Translation Amounts in NOK thousand Share capitalShare premium Retained earnings Total equity capital differences Balance at January 1, 2021 5 097 87 065 11 800 103 963 -83 284 -330
Slide 23: Cash flow statement
UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2022 Cash flow statement (Amounts iin NOK thousand Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 Cash flow from operating activities Result before tax -8 142 1 335 -17 149 -3 484 -26 321 Tax paid -206 0 -120 0 -192 Depreciation and amortisation 3 403 819 5 116 1 616
Slide 24: Top 20 shareholders
AS OF 22 AUGUST 2022 Top 20 shareholders Rank Name Number of shares % of top 20 % of total Country 1 INGERØ REITEN INVESTMENT COMPANY AS 9 653 680 27.63 % 18.05 % Norway 2 NAVAMEDIC ASA 4 222 727 12.09 % 7.89 % Norway 3 JPB AS 2 830 209 8.10 % 5.29 % Norway 4 RO, LARS 2 673 762 7.65 % 5.00 % Norway
Slide 25: Definitions of Alternative Performance Measures (APM)
OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result EBITDA
Slide 26: oReonserve
oReonserve medical